Sarcopenia: An Important Entity Still Underinvestigated in Heart Failure

Overview

Journal Arq Bras Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Aug 9

PMID 37556659

Authors

Roberto Magalhaes Saraiva

Andrea Rodrigues da Costa

Affiliations

Soon will be listed here.

References

Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J . The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014; 99(11):4336-45. DOI: 10.1210/jc.2014-1742. View

Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W . Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2012; 34(7):512-9. DOI: 10.1093/eurheartj/ehs381. View

Chen R, Xu J, Wang Y, Jiang B, Xu X, Lan Y . Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review. Clin Cardiol. 2023; 46(3):260-268. PMC: 10018088. DOI: 10.1002/clc.23970. View

Burton L, McMurdo M, Struthers A . Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?. Clin Endocrinol (Oxf). 2011; 75(6):725-9. DOI: 10.1111/j.1365-2265.2011.04148.x. View

Evans W . Functional and metabolic consequences of sarcopenia. J Nutr. 1997; 127(5 Suppl):998S-1003S. DOI: 10.1093/jn/127.5.998S. View

Sangali T, Souza G, Ribeiro E, Perry I . Sarcopenia: Inflammatory and Humoral Markers in Older Heart Failure Patients. Arq Bras Cardiol. 2023; 120(7):e20220369. PMC: 10382140. DOI: 10.36660/abc.20220369. View

Cho J, Choi Y, Sajgalik P, No M, Lee S, Kim S . Exercise as a Therapeutic Strategy for Sarcopenia in Heart Failure: Insights into Underlying Mechanisms. Cells. 2020; 9(10). PMC: 7602002. DOI: 10.3390/cells9102284. View

Fernandez-Pombo A, Rodriguez-Carnero G, Castro A, Canton-Blanco A, Seoane L, Casanueva F . Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure. Clin Nutr. 2021; 40(9):5141-5155. DOI: 10.1016/j.clnu.2021.07.027. View

Onoue Y, Izumiya Y, Hanatani S, Tanaka T, Yamamura S, Kimura Y . A simple sarcopenia screening test predicts future adverse events in patients with heart failure. Int J Cardiol. 2016; 215:301-6. DOI: 10.1016/j.ijcard.2016.04.128. View

10.

Bielecka-Dabrowa A, Ebner N, Dos Santos M, Ishida J, Hasenfuss G, von Haehling S . Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail. 2020; 22(12):2314-2326. DOI: 10.1002/ejhf.2011. View

11.

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

12.

Dodds R, Granic A, Davies K, Kirkwood T, Jagger C, Sayer A . Prevalence and incidence of sarcopenia in the very old: findings from the Newcastle 85+ Study. J Cachexia Sarcopenia Muscle. 2016; 8(2):229-237. PMC: 5377385. DOI: 10.1002/jcsm.12157. View

13.

Zhou L, Xu L, Wang X, Huang Y, Xiao Q . Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis. Drugs Aging. 2015; 32(9):727-35. DOI: 10.1007/s40266-015-0288-3. View

14.

Anker S, Negassa A, Coats A, Afzal R, Poole-Wilson P, Cohn J . Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003; 361(9363):1077-83. DOI: 10.1016/S0140-6736(03)12892-9. View

15.

Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V . Sarcopenia and Heart Failure. Nutrients. 2020; 12(1). PMC: 7019352. DOI: 10.3390/nu12010211. View